gms | German Medical Science

102. Jahrestagung der DOG

Deutsche Ophthalmologische Gesellschaft e. V.

23. bis 26.09.2004, Berlin

Enzyme-assisted vitrectomy: demands and reality

Meeting Abstract

Search Medline for

  • corresponding author A. Gandorfer - Augenklinik der LMU, München
  • A. Kampik - Augenklinik der LMU, München
  • The Microplasmin Study Group - Augenklinik der LMU, München

Evidenzbasierte Medizin - Anspruch und Wirklichkeit. 102. Jahrestagung der Deutschen Ophthalmologischen Gesellschaft. Berlin, 23.-26.09.2004. Düsseldorf, Köln: German Medical Science; 2004. Doc04dogSO.01.01

The electronic version of this article is the complete one and can be found online at:

Published: September 22, 2004

© 2004 Gandorfer et al.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( You are free: to Share – to copy, distribute and transmit the work, provided the original author and source are credited.



Many enzymes have been used in ocular surgery, and in particular in vitreoretinal surgery. The common goal of such surgery is to achieve posterior vitreous detachment (PVD) or vitreous liquification (vitreolysis). Previous and current concepts are discussed in this lecture. Plasmin holds the promise to create a clean vitreoretinal surface by inducing complete PVD, as shown by several pre-clincal studies. In these reports, the ultrastructure of the retina was unchanged following application of the enzyme. Autologous plasmin is effectively administered before macular surgery without inducing untowards effects to the retina. In pre-clinical studies, Microplasmin (ThromboGenics Ltd., Dublin), a truncated molecule containing the catalytic domaine of human plasmin, has been shown to create complete PVD without changing the ultrastructure and antigenity of the retina. Clinical studies with Microplasmin and autologous plasmin are underway, and will be introduced in this lecture.